TheraRadar

Repros

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 7/26/2016

50
Total Trials
13
Phase 3
19
Phase 2
0
Recruiting
407
Score

Pipeline by Phase

Phase 3
13
Phase 2
19
Phase 1
20

Therapeutic Focus

Uterine Fibroids Secondary Hypogonadism Healthy Endometriosis Pharmacokinetics

Clinical Trials (50)

NCT01532414 Phase 3 COMPLETED

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Started: 8/1/2012

NCT01739595 Phase 3 COMPLETED

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Started: 11/1/2012

NCT01993212 Phase 3 COMPLETED

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Started: 1/1/2014

NCT01619683 Phase 3 COMPLETED

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Started: 9/1/2012

NCT01993225 Phase 3 COMPLETED

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Started: 1/1/2014

NCT00853567 Phase 3 TERMINATED

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Started: 2/1/2009

NCT00785356 Phase 3 TERMINATED

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Started: 10/1/2008

NCT00735553 Phase 3 TERMINATED

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Started: 8/1/2008

NCT00737282 Phase 3 TERMINATED

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Started: 10/1/2008

NCT01069120 Phase 3 TERMINATED

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Started: 4/1/2009

NCT00702702 Phase 3 TERMINATED

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Started: 6/1/2008

NCT01534208 Phase 3 COMPLETED

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Started: 5/1/2012

NCT01739582 Phase 3 COMPLETED

An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Started: 11/1/2012

NCT01728454 Phase 2 COMPLETED

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Started: 5/2/2013

NCT02651688 Phase 2 COMPLETED

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Started: 1/11/2016

NCT02811159 Phase 2 TERMINATED

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Started: 7/26/2016

NCT02323646 Phase 2 COMPLETED

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Started: 2/12/2015

NCT02301897 Phase 2 COMPLETED

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Started: 3/16/2015

NCT00958412 Phase 2 TERMINATED

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Started: 2/28/2009

NCT01386606 Phase 2 COMPLETED

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Started: 6/1/2011

NCT00706719 Phase 2 COMPLETED

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Started: 6/1/2008

NCT01451424 Phase 2 COMPLETED

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Started: 2/1/2012

NCT00958893 Phase 2 TERMINATED

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Started: 6/1/2008

NCT00683917 Phase 2 TERMINATED

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Started: 5/1/2008

NCT01270841 Phase 2 COMPLETED

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Started: 1/1/2011

NCT01191320 Phase 2 COMPLETED

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

Started: 10/1/2010

NCT01739621 Phase 2 COMPLETED

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Started: 9/1/2012

NCT01631903 Phase 2 COMPLETED

Extension of Study ZPV-200

Started: 9/1/2012

NCT01961908 Phase 2 WITHDRAWN

Open-Label Extension Study to ZPE-202

Started: 12/1/2013

NCT01386567 Phase 2 COMPLETED

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

Started: 7/1/2011

NCT00620503 Phase 1 COMPLETED

Proellex® Pharmacokinetic Bridging Study II

Started: 2/29/2008

NCT01984398 Phase 1 COMPLETED

Comparison of Two Formulations of Androxal

Started: 12/31/2013

NCT00749879 Phase 1 COMPLETED

Crossover Study of the Safety and PK Properties of Proellex®

Started: 8/11/2008

NCT02274181 Phase 1 COMPLETED

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

Started: 12/1/2014

NCT02169804 Phase 1 COMPLETED

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

Started: 8/1/2014

NCT02141061 Phase 1 COMPLETED

Comparison of Two Formulations of Proellex for Oral Administration

Started: 5/1/2014

NCT00741273 Phase 1 COMPLETED

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Started: 10/1/2008

NCT00787618 Phase 1 TERMINATED

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Started: 10/1/2008

NCT00881608 Phase 1 TERMINATED

Study to Evaluate Menses Induction in Women Administered Proellex

Started: 2/1/2009

NCT00741468 Phase 1 COMPLETED

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Started: 7/1/2008

NCT01923857 Phase 1 COMPLETED

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Started: 8/1/2013

NCT01991327 Phase 1 COMPLETED

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

Started: 5/1/2014

NCT01959685 Phase 1 COMPLETED

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Started: 10/1/2013

NCT02146391 Phase 1 COMPLETED

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

Started: 6/1/2014

NCT00619385 Phase 1 COMPLETED

A Safety and Pharmacokinetic Study of Proellex®

Started: 2/1/2008

NCT01187043 Phase 1 COMPLETED

Determination of the Lowest, Safe and Effective Dose of Proellex

Started: 8/1/2010

NCT00881062 Phase 1 COMPLETED

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

Started: 4/1/2009

NCT02117830 Phase 1 COMPLETED

A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects

Started: 4/1/2014

NCT01923870 Phase 1 COMPLETED

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Started: 8/1/2013

NCT01962805 Phase 1 COMPLETED

Comparison of Two Formulations of Proellex for Vaginal Administration

Started: 10/1/2013

Drug Candidates

Placebo Telapristone acetate Enclomiphene Telapristone Acetate Proellex 25 mg formulation A Proellex 25 mg formulation B 12.5 mg Androxal Formulation A 12.5 mg Androxal Formulation B 25 mg Androxal Formulation A 25 mg Androxal Formulation B
Activity Status: Inactive
Last Trial Started: 7/26/2016
Last Trial Ended: 6/2/2017
Trials (12 months): 0
Completed Trials: 37
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.